Distinguished in MYH9 Related Thrombocytopenia

Andreas Greinacher

Ferdinand Sauerbruch Str, 
Greifswald, MV, DE 
Distinguished in MYH9 Related Thrombocytopenia
Ferdinand Sauerbruch Str, 
Greifswald, MV, DE 
OverviewLocationsClinical Research

Overview

Andreas Greinacher practices in Greifswald, Germany. Greinacher is rated as a Distinguished expert by MediFind in the treatment of MYH9 Related Thrombocytopenia. Their top areas of expertise are Thrombocytopenia, Purpura, Adult Immune Thrombocytopenia, Immune Thrombocytopenic Purpura (ITP), and Bone Marrow Transplant.

Their clinical research consists of co-authoring 372 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 4 articles in the study of MYH9 Related Thrombocytopenia.

Locations

Ferdinand Sauerbruch Str, Greifswald, MV 17475, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

Liberal Transfusion Strategy to Prevent Mortality and Anaemia-associated, Ischaemic Events in Elderly Non-cardiac Surgical Patients
Liberal Transfusion Strategy to Prevent Mortality and Anaemia-associated, Ischaemic Events in Elderly Non-cardiac Surgical Patients
Enrollment Status: Active_not_recruiting
Publish Date: August 07, 2025
Intervention Type: Drug
Study Phase: Phase 3
Screening for SARS-CoV-2-Infections and Monitoring of Serological Responses to SARS-CoV-2 in Healthcare Workers
Screening for SARS-CoV-2-Infections and Monitoring of Serological Responses to SARS-CoV-2 in Healthcare Workers
Enrollment Status: Active_not_recruiting
Publish Date: May 09, 2024
Intervention Type: Diagnostic test
Open-Label, Randomised, Active Controlled, Multi-Centre Ph 3 Study to Evaluate the Safety and Efficacy of Danaparoid vs Argatroban in Acute HIT
Open-Label, Randomised, Active Controlled, Multi-Centre Ph 3 Study to Evaluate the Safety and Efficacy of Danaparoid vs Argatroban in Acute HIT
Enrollment Status: Terminated
Publish Date: December 08, 2022
Intervention Type: Drug
Study Phase: Phase 3
View 2 Less Clinical Trials

372 Total Publications

Antiplatelet factor 4 (PF4)-associated disorders: from drug adverse reactions to thrombotic disease
Antiplatelet factor 4 (PF4)-associated disorders: from drug adverse reactions to thrombotic disease
Journal: Innere Medizin (Heidelberg, Germany)
Published: June 06, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Greinacher's expertise for a condition
ConditionClose
View All 8 Advanced Conditions
View All 32 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile